Pharma Q3 Earnings Preview: Domestic Formulation Fails To Pick Up, Says Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
In our coverage universe, we expect Q3 FY21E Revenue/Ebitda/profit before tax growth of 9%/30%/42% YoY for pharmaceuticals companies whereas Revenue/Ebitda/PBT growth of 22%/28%/32% YoY for diagnostic companies.
1. India formulations core portfolio growth to be only in mid/lower-single digit for most companies even after marketing activities and spends reach pre-Covid-19 level.
2. U.S. QoQ growth to be company-specific with selective products driving growth while specialty products sales to be better and also reached pre-Covid-19 levels,
3. Emerging market’s and Rest-of-world growth could rationalize after higher growth in Q2 due to clearance of order backlog due to logistic restriction in Q1.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.